The 32 most recent market catalysts affecting $SYK, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 18, 2026
Corporate Catalyst
Neutral
Impact 75
Synektik S.A. Reports Financial Results
Synektik S.A. released its financial results, disclosing a net profit of 402,690.75 and EPS of 47.21, along with net cash flows from operating activities of 128,810.11. This inform…
Nov 18, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Adjusts Price Target on Stryker to $345 From $304
Investment firm BTIG has raised its price target for Stryker (SYK) from $304 to $345, while keeping a 'Buy' rating. This analyst action signals a positive re-evaluation of Stryker'…
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Adjusts Price Target on Stryker to $350 From $325
Piper Sandler, an investment firm, has raised its price target for Stryker Corporation (SYK) from $325 to $350. This adjustment signals a more favorable view of Stryker's valuation…
Nov 2, 2026
Corporate Catalyst
Neutral
Impact 65
Analysts Adjust Ratings and Price Targets for Stryker Following Q3 Performance
Following Stryker's third-quarter earnings, several analysts adjusted their outlooks. Truist Securities maintained a Hold but lowered its price target, Stifel maintained a Buy but …
Nov 2, 2026
Corporate Catalyst
Bearish
Impact 55
Rothschild & Co Redburn Adjusts Price Target on Stryker
Rothschild & Co Redburn adjusted its price target for Stryker Corporation, reducing it from $360 to $336. This action signifies a more conservative valuation by the analyst firm, p…
Oct 30, 2026
Corporate Catalyst
Neutral
Impact 75
Multiple Financial Institutions Adjust Price Targets for Stryker
Following Stryker's Q3 2026 earnings, several prominent financial institutions, including RBC Capital Markets and Deutsche Bank, significantly reduced their price targets for the c…
Oct 30, 2026
Corporate Catalyst
Bullish
Impact 85
Stryker Reports Third Quarter 2026 Financial Results and Increases Share Repurchase Authorization
Stryker reported Q3 2026 results that, while showing growth in net sales and adjusted EPS, fell short of management's expectations, indicating potential operational challenges or a…
Oct 30, 2026
Corporate Catalyst
Neutral
Impact 75
Analysts Adjust Price Targets for Stryker Following Q3 Results
Following Stryker Corporation's Q3 2026 earnings release, several major analysts, including Barclays, Baird, Needham, and JPMorgan, significantly reduced their price targets for th…
Oct 29, 2026
Corporate Catalyst
Bullish
Impact 85
Stryker Reports Third Quarter 2026 Operating Results
Stryker's Q3 2026 earnings report indicates strong operational health, with both reported and organic net sales increasing by 7.7% and adjusted EPS rising by 10.3%. The significant…
Oct 29, 2026
Corporate Catalyst
Neutral
Impact 55
Stryker's Prophecy Incompass Instrumentation Used in First Total Ankle Replacement
Stryker announced the successful first total ankle replacement surgery utilizing its new Prophecy Incompass patient-specific instrumentation. This event, occurring in July 2026, si…
Oct 28, 2026
Corporate Catalyst
Bullish
Impact 55
Evercore ISI Adjusts Stryker Price Target to $355
Evercore ISI has raised its price target for Stryker Corporation (SYK) from $335 to $355. This change reflects an updated valuation analysis by the firm, suggesting increased confi…
Oct 26, 2026
Corporate Catalyst
Bullish
Impact 75
Stryker Completes Acquisition of ZuriMED
Stryker Corporation has completed its acquisition of ZuriMED, a privately held company focused on shoulder repair technology. This acquisition is significant as it directly enhance…
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 65
Synektik S.A. Signs Significant Supply Contract with University Hospital in Krakow
Synektik S.A. announced a significant contract win with the University Hospital in Krakow for the supply of consumables for da Vinci robotic surgery systems. This 24-month agreemen…
Oct 12, 2026
Corporate Catalyst
Bearish
Impact 55
BTIG Maintains Buy on Stryker, Lowers Price Target to $316
BTIG analyst Ryan Zimmerman has reduced the price target for Stryker (SYK) from $358 to $316, although the 'Buy' rating remains unchanged. This action indicates that while the anal…
Oct 7, 2026
Corporate Catalyst
Bearish
Impact 55
Truist Securities Maintains Hold on Stryker, Lowers Price Target to $310
Truist Securities analyst Richard Newitter has adjusted his price target for Stryker (SYK) from $340 to $310, while keeping a 'Hold' rating on the stock. This action signals a more…
Oct 7, 2026
Corporate Catalyst
Neutral
Impact 55
Barclays Initiates Coverage On Stryker with Overweight Rating, Announces Price Target of $375
Barclays analyst Christopher Pasquale initiated coverage on Stryker (SYK) with an Overweight rating and a $375 price target. This is a positive development for Stryker as it signal…
Oct 6, 2026
Corporate Catalyst
Neutral
Impact 65
Stryker Appoints President, COO Spencer Stiles As CEO, Effective January 2027, Succeeding Kevin Lobo, Who Will Transition To Executive Chair
Stryker announced a long-term CEO succession plan, with Spencer Stiles, the current President and COO, slated to become CEO in January 2027. Kevin Lobo, the current CEO, will trans…
Sep 30, 2026
Corporate Catalyst
Bearish
Impact 55
Stifel Maintains Buy on Stryker, Lowers Price Target to $330
Stifel analyst Rick Wise has maintained a 'Buy' rating on Stryker (SYK) but has lowered the price target from $360 to $330. This adjustment suggests that while the analyst still se…
Sep 22, 2026
Corporate Catalyst
Bearish
Impact 55
TD Cowen Maintains Hold on Stryker, Lowers Price Target to $298
TD Cowen analyst Mathew Blackman maintained a 'Hold' rating on Stryker (SYK) but lowered the price target from $355 to $298. This action indicates a revised valuation perspective f…
Sep 9, 2026
Corporate Catalyst
Bearish
Impact 55
Wells Fargo Maintains Overweight on Stryker, Lowers Price Target to $348
Wells Fargo analyst Larry Biegelsen maintained an 'Overweight' rating on Stryker (SYK), indicating a positive long-term outlook for the company. However, the price target was signi…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 65
Stryker Announces Deal To Acquire Rotator Cuff Augmentation Firm ZuriMED; Terms Not Disclosed
This acquisition by Stryker (SYK) is a strategic move to enhance its sports medicine offerings, specifically in rotator cuff repair. While the financial terms are undisclosed, the …
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 60
Citizens Maintains Market Outperform on Stryker, Lowers Price Target to $400
Citizens analyst David Turkaly has adjusted Stryker's (SYK) price target down to $400 from $440, while reaffirming a 'Market Outperform' rating. This move suggests that while the a…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Stryker, Lowers Price Target to $420
RBC Capital analyst Kendall Au maintained an 'Outperform' rating on Stryker (SYK) but lowered the price target from $435 to $420. This action signals that while the analyst still v…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 65
JP Morgan Maintains Overweight on Stryker, Lowers Price Target to $350
JP Morgan's decision to lower Stryker's price target from $400 to $350, while maintaining an 'Overweight' rating, suggests a recalibration of valuation expectations rather than a f…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 55
Piper Sandler Maintains Overweight on Stryker, Lowers Price Target to $390
Piper Sandler analyst Matt O'Brien maintained an 'Overweight' rating on Stryker but lowered the price target from $420 to $390. This action signals that while the analyst still bel…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 75
Stryker shares are trading lower after the company reported Q2 financial results. BTIG lowered its price target on the stock from $371 to $358.
The headline signals a negative corporate catalyst for Stryker, driven by Q2 financial results that likely fell short of analyst expectations or guidance. The subsequent price targ…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 95
Stryker Q2 Adj. EPS $5.75 Beats $3.49 Estimate, Sales $6.589B Beat $6.579B Estimate
Stryker (SYK) announced Q2 adjusted EPS of $5.75, significantly surpassing the analyst consensus of $3.49, an 83.71% increase year-over-year. Sales also beat estimates, coming in a…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 85
Correction: Stryker Q2 Adj. EPS $3.69 Beats $3.49 Estimate, Sales $6.589B Beat $6.579B Estimate
Stryker announced its second-quarter earnings, revealing adjusted EPS of $3.69, which significantly beat the analyst consensus of $3.49 by 5.73%. Sales also surpassed expectations,…
Jul 14, 2026
Corporate Catalyst
Bearish
Impact 85
Shares of medical device-related companies are trading lower after HCA Healthcare noted a Q2 increase in uninsured patient volumes and a decline in surgical volume, which may dim the outlook for device pricing power and margins.
HCA Healthcare's report acts as a bellwether for the broader healthcare services sector, particularly for companies reliant on elective procedures. The increase in uninsured patien…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.